Abstract: This invention provides a polymer that is useful in a variety of applications, including as a binder polymer of a coating composition, and especially a packaging coating composition. Packaging articles (e.g., containers) comprising the polymer and methods of making such packaging articles are also provided.

Abstract: Embodiments relate to systems and methods for secure medical communication. The system can be implemented in a hospital or other health care setting. Recipient devices, such as smartphones, associated with family members or other authorized users can be registered to a notification engine to receive automatic distributions of patient updates or other medical information entered for the patient by doctors, nurses, or other care providers. In implementations, the entire system is secure and capable of compliance with privacy or other regulations, such as HIPPA or others. In implementations, the entry of an update to the patient's medical information can trigger the delivery of a text message or other notification of that update to the set of registered devices, on an immediate or automatic basis The recipients are accordingly relieved of any need to call in to a hospital unit or take other positive actions to receive medical information.

Abstract: A new and distinct cultivar of flowering dogwood, which has fused bracts is provided. This dogwood is botanically known as Cornus kousa and referred to by the following cultivar name: ‘Pam's Mountain Bouquet’.

Abstract: The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% w/v, a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 200-400 mOsm/kG, at a pH between 4 to 8, wherein the latrunculin, the surfactant, and the tonicity agent are compatible in the formulation, and the formulation does not contain a substantial amount of dimethyl sulfoxide. The formulation is stable for at least six month at refrigerated temperature. The present invention further provides a method of reducing intraocular pressure, a method of treating glaucoma, a method of inhibiting wound healing after trabeculectomy, and a method of inhibiting angiogenesis.

Abstract: The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% w/v, a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 200-400 mOsm/kG, at a pH between 4 to 8, wherein the latrunculin, the surfactant, and the tonicity agent are compatible in the formulation, and the formulation does not contain a substantial amount of dimethyl sulfoxide. The formulation is stable for at least six month at refrigerated temperature. The present invention further provides a method of reducing intraocular pressure, a method of treating glaucoma, a method of inhibiting wound healing after trabeculectomy, and a method of inhibiting angiogenesis.

Abstract: The present invention provides a method for the production of medicinal aerosol compositions which are made up of a homogenous solution of aerosol propellants, a surfactant and a pharmaceutically active compound, where the process comprises purifying the surfactant, removing the water from the surfactant, and dispersing the surfactant in an aerosol propellant with a hydrophilic pharmaceutical composition and a controlled amount of water. The present invention also provides medicinal aerosol compositions produced by this method which are a homogenous solution of the pharmaceutically active compound contained in reverse micelles made up of the surfactant; and methods of using the medicinal aerosols to provide an effective amount of a therapeutic agent.

Abstract: Highly purified and recombinantly produced polypeptides and proteins can be provided to a patient to treat systemic disorders using a metered dose inhaler (MDI). The polypeptides and proteins are solubilized in reverse micelles formed from the surfactant in the MDI propellant. By controlling the molar ratio of water to surfactant, the amount of polypeptide or protein solubilized in the reverse micelles can be controlled, thereby providing an accurate dosing mechanism. In addition, controlling the molar ratio of water to surfactant also can adjust the size and shape of the reverse micelles which will affect the degree and rate of penetration of the lung mucosa for delivery of the drugs to the patient's blood stream. Proteins which may particularly benefit from the solubilization and systemic delivery process include calcitonin, oxytocin, and insulin.

Abstract: A new and distinct cultivar of flowering dogwood tree, which has fused bracts is provided. This dogwood tree is botanically known as Cornus kousa and referred to by the following cultivar name: ‘Pam's Mountain Bouquet’.